HedgeChatter

  • Home /
  • Tag Archives

SGEN

Narrower-than-Expected Loss at Seattle Genetics

moreView todays social media effects on SGENView the latest stocks trending across Twitter. Click to view dashboardSee who Seattle is hiring next, click here to view […]

February 12, 2014 Bystocknews , Comments Off on Narrower-than-Expected Loss at Seattle Genetics read more

Seattle Genetics Reports Fourth Quarter and Year 2013 Financial Results

[at noodls] – -Total 2013 Revenues of $269.3 Million, Including $144.7 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Product Sales- -Data Anticipated in 2014 from ADCETRIS Phase 3 AETHERA Trial and … moreView todays social media effects on SGENView the latest stocks trending across Twitter. Click to view dashboardSee who Seattle is hiring next, click here to view […]

February 12, 2014 Bystocknews , Comments Off on Seattle Genetics Reports Fourth Quarter and Year 2013 Financial Results read more

4:12 pm Seattle Genetics beats by $0.11, beats on revs; Data anticipated in 2014 from ADCETRIS Phase 3 AETHERA trial and SGN-CD19A and SGN-CD33A pipeline programs

moreView todays social media effects on SGENView the latest stocks trending across Twitter. Click to view dashboardSee who Seattle is hiring next, click here to view […]

February 12, 2014 Bystocknews , Comments Off on 4:12 pm Seattle Genetics beats by $0.11, beats on revs; Data anticipated in 2014 from ADCETRIS Phase 3 AETHERA trial and SGN-CD19A and SGN-CD33A pipeline programs read more

4:12 pm Seattle Genetics beats by $0.11, beats on revs; Data anticipated in 2014 from ADCETRIS Phase 3 AETHERA trial and SGN-CD19A and SGN-CD33A pipeline programs

moreView todays social media effects on SGENView the latest stocks trending across Twitter. Click to view dashboardSee who Seattle is hiring next, click here to view […]

February 11, 2014 Bystocknews , Comments Off on 4:12 pm Seattle Genetics beats by $0.11, beats on revs; Data anticipated in 2014 from ADCETRIS Phase 3 AETHERA trial and SGN-CD19A and SGN-CD33A pipeline programs read more

Seattle Genetics Reports Fourth Quarter and Year 2013 Financial Results

[Business Wire] – Seattle Genetics, Inc. today reported financial results for the fourth quarter and year ended December 31, 2013. The company also highlighted ADCETRIS (brentuximab v moreView todays social media effects on SGENView the latest stocks trending across Twitter. Click to view dashboardSee who Seattle is hiring next, click here to view […]

February 11, 2014 Bystocknews , Comments Off on Seattle Genetics Reports Fourth Quarter and Year 2013 Financial Results read more